is a biopharmaceutical company focused on the development of
novel treatments for B-cell malignancies and autoimmune diseases.
Click for full image >>
TG Therapeutics, Inc. Announces Preclinical Data Presentation on the Company's Anti-PD-L1 Monoclonal Antibody at the 2017 American Association for Cancer Research Annual Meeting
TG Therapeutics, Inc Announces Preclinical Data Presentation at the 2017 American Association for Cancer Research (AACR) Annual Meeting
2 Gansevoort Street, 9th Floor, New York NY 10014 - P:212.554.4484 - Email Us
Web Site Development by Tidal Media Group